Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Helsinn Group
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Sep 15, 2023
Management Tracks
O’Callaghan to lead Deep Genomics as CEO
Plus: Pliant hires Kuo and updates for Helsinn Group, Sling, Repairon, Nusano and Fractyl
BioCentury | Jan 9, 2023
Management Tracks
Sanofi’s Zehnder to lead CureVac
Plus: new CEOs at Novavax, Intergalactic, Evoq and Helsinn, and updates from ADARx, Acadia and more
BioCentury | Oct 1, 2022
Product Development
Sept. 30 Quick Takes: Intercept NASH candidate fails Phase III, NDA resubmission on track
Plus Zealand to advance glepaglutide to NDA and updates from Valneva and YS Pharma
BioCentury | Sep 8, 2022
Product Development
Relay racing down accelerated pathway with promising bile duct cancer readout
Latest data cut shows response rates to computationally designed selective FGFR2 inhibitor, built for efficacy with improved safety profile
BioCentury | May 20, 2022
Management Tracks
Schoenfeld becomes Mark Foundation CEO
Plus new CDO at iosBio, and updates from Cerebral, Helsinn, CureDuchenne and more
BioCentury | Apr 21, 2022
Deals
Investors look behind the curtain of pharma-biotech deals
Having a big-name deal is no longer the validating event for a young biotech that it once was
BioCentury | Mar 11, 2022
Deals
March 10 Quick Takes: Scenic heads to clinic with $31M series A
Plus AbbVie, Venatorx meet in Phase III and updates from MorphoSys, RefleXion, TG Therapeutics, Xeris and more
BioCentury | Mar 31, 2021
Finance
March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos
Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell
Items per page:
1 - 10 of 17